ESMO 2026 Conference Intelligence

[Slide 1] ESMO 2026 PRESIDENTIAL SYMPOSIUM LBAs — key late-breaking trials that may shape tomorrow's oncology practice. New data · Bigger insights · Better care. PRESIDENTIAL SYMPOSIUM I | 24 OCT 2026 — 4 late-breaking abstracts: 1. LBA1 – INTerpath-001 (Melanoma): Intismeran autogene + pembrolizumab vs pembrolizumab alone in adjuvant treatment of resected stage IIB–IV melanoma. 2. LBA2 – VOLGA (Bladder cancer): Perioperative durvalumab ± tremelimumab + neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer. 3. LBA3 – DeLLphi-305 (Small cell lung cancer): Tarlatamab + durvalumab vs durvalumab as 1L maintenance after durvalumab + platinum + etoposide in ES-SCLC. 4. LBA4 – DASL-HiCaP (ANZUP1801) (Prostate cancer): Darolutamide + ADT + definitive/salvage locoregional RT for localized, very high-risk prostate cancer. PRESIDENTIAL SYMPOSIUM II | 25 OCT 2026 — 4 late-breaking abstracts: 5. LBA5 – KRAScendo 1 (NSCLC, KRAS G12C): Divarasib vs sotorasib or adagrasib in previously treated locally advanced/metastatic KRAS G12C-mutated NSCLC. 6. LBA6 – SAFFRON (NSCLC, EGFR/MET): Osimertinib + savolitinib vs platinum–pemetrexed in EGFR-mutated, MET-overexpressed/amplified advanced NSCLC after osimertinib. 7. LBA7 – CLARITY-Gastric 01 (CG-01) (Gastroesophageal cancer): Sonesitatug vedotin in 2L+ advanced/metastatic CLDN18.2-positive gastroesophageal carcinoma. 8. LBA8 – HARMONi-GI1 (Biliary tract cancer): Ivonescimab + chemotherapy vs durvalumab + chemotherapy as first-line treatment for advanced biliary tract cancer. PRESIDENTIAL SYMPOSIUM III | 26 OCT 2026 — 4 late-breaking abstracts: 9. LBA9 – ARTEMIS-011 (Osteosarcoma): Risvutatug rezetecan vs gemcitabine + docetaxel in heavily pretreated relapsed/refractory osteosarcoma. 10. LBA10 – MIOIO (Multiple solid tumours): Reduced-frequency immune checkpoint inhibitors in responding patients with advanced/metastatic cancer — phase III randomized non-inferiority trial. 11. LBA11 – TroFuse-005 / ENGOT-en123 / GOG-3095 (Endometrial cancer): Sacituzumab tirumotecan in previously treated advanced or recurrent endometrial cancer. 12. LBA12 – KEYNOTE-C93 / GOG-3064 / ENGOT-en15 (Endometrial cancer): First-line pembrolizumab vs carboplatin + paclitaxel in dMMR advanced/recurrent endometrial carcinoma. 12 Late-Breaking Abstracts • ESMO Congress 2026.

[Slide 1] ESMO 2026 — Lung Cancer Presidential Highlights. Presidential Symposium presentations. Based on current official programme. Madrid, Spain · 23–27 October 2026. Presidential Symposium I — Sat, 24 Oct 2026, 16:30–18:15, Alicante Auditorium – Hall 6. Presidential Symposium II — Sun, 25 Oct 2026, 16:30–18:15, Alicante Auditorium – Hall 6. 01 · LBA3 | DeLLphi-305 — Tarlatamab + durvalumab vs durvalumab. 1L maintenance after durvalumab + platinum/etoposide in ES-SCLC. Phase 3 | Primary endpoint: OS. Presenter: Jacob Sands. Presidential Symposium I, Sat, 24 Oct 2026, 16:30–18:15, Hall 6. 02 · LBA5 | Krascendo 1 — Divarasib vs sotorasib or adagrasib. Previously treated advanced/metastatic KRAS G12C NSCLC. Phase 3 | Primary endpoint: PFS. Presenter: Ferdinandos Skoulidis. Presidential Symposium II, Sun, 25 Oct 2026, 16:30–18:15, Hall 6. 03 · LBA6 | SAFFRON — Osimertinib + savolitinib vs platinum–pemetrexed. EGFR-mutant MET-overexpressed and/or amplified advanced NSCLC post-osimertinib. Phase 3 | Primary endpoint: PFS. Presenter: Shun Lu. Presidential Symposium II, Sun, 25 Oct 2026, 16:30–18:15, Hall 6.

[Slide 1 — Gastroesophageal] Upper GI oral abstracts #ESMO26 (@Erman_Akkus): • LBA7 - CLARITY-Gastric 01 (CG-01): a Phase 3 study of sonesitatug vedotin (Sone-Ve) in second or later-line (2L+) advanced or metastatic Claudin 18.2 (CLDN18.2) positive gastroesophageal carcinoma (GEC) • LBA77 - Arcotatug tavatecan (IBI343/TAK-921) versus treatment of physician's choice (TPC) in previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA): First interim analysis of the randomized, open-label, phase 3, G-HOPE-001 study • LBA78 - Active surveillance versus standard surgery after neoadjuvant chemoradiotherapy for oesophageal cancer: long-term results of a cluster-randomised controlled trial (SANO) • 2875O - Pembrolizumab or placebo plus concurrent definitive chemoradiotherapy in esophageal and gastroesophageal junction (GEJ) cancer: the Phase 3 randomized KEYNOTE-975 study • LBA80 - Anbenitamab plus chemotherapy for previously treated HER2-positive gastric or gastroesophageal carcinomas (GC/GEJC): Updated overall survival (OS) analysis of KC-WISE • 2876RO - TQB2102, a Novel HER2 Bispecific Antibody-Drug Conjugate, Combined with Bemotrizumab with or without Capecitabine as First-Line Therapy for HER2-Positive Advanced Gastric/Gastroesophageal Junction Cancer: A Phase II Study • 2877RO - Watch-and-wait (W&W) strategy for dostarlimab in localized deficient dMMR/MSI-H gastroesophageal adenocarcinoma (GEA): Results from the first interim analysis of the GERCOR-GONO DEWI phase II study • 2878RO - FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for taxane-pretreated patients with advanced or metastatic gastroesophageal adenocarcinoma–Final results of the phase III IKFs602/AIO RAMIRIS Study • LBA81 - Four Months of Adjuvant XELOX versus Six Months in Stage II–IIIB Gastric Cancer — The LOMAC Randomized Trial • 2879RO - Durvalumab plus definitive chemoradiotherapy versus definitive chemoradiotherapy in patients with locally advanced esophagus carcinoma: ARION PRODIGE 67 randomized phase 2 trial • 2883RO - Efficacy Of Bemarituzumab In Patients With Advanced Gastric and Gastroesophageal Junction Cancer (GC/GEJ) by FGFR2 Amplification Status: Exploratory Biomarker Analysis from FORTITUDE-101 (F101) and FORTITUDE-102 (F102) • 1008RO - IBI363 (TAK-928) plus XELOX as the first line (1L) treatment for advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA) • 4252RO - GDF-15–Associated Adipose CD8+ T-Cell Exhaustion Links Subcutaneous Fat Wasting to Poor Outcomes During PD-1 Inhibitor-Based Chemotherapy in Gastric Cancer [Slide 2 — Biliary-HCC] • LBA8 - Ivonescimab plus chemotherapy versus durvalumab plus chemotherapy as first-line treatment for advanced biliary tract cancer: a randomized, controlled, double-blinded, phase 3 trial (HARMONi-GI1) • 459O - A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer • LBA21 - Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and gallbladder carcinoma (ACTICCA-1 trial) • LBA22 - OPTIMUM: A randomized phase 2 study of maintenance olaparib (Ola) with or without durvalumab (Durva) in DDR gene-mutated advanced biliary tract cancer (aBTC) • 473RO - Subcutaneous anti-PD-L1 monoclonal antibody Envafolimab plus gemcitabine and oxaliplatin (GEMOX) versus GEMOX alone as first-line treatment for advanced biliary tract cancer in Chinese patients: A randomized, open-label, multicenter, registrational phase III trial • LBA48 - Liver function trajectory and post-progression outcomes in the Phase 3 EMERALD-3 study of tremelimumab (T) + durvalumab (D) ± lenvatinib (L) + transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible hepatocellular carcinoma (eeHCC) • 1679O - Phase 1 study of BGB-B2033 (GPC3 x 4-1BB bispecific antibody) Monotherapy: First Disclosure of Dose Optimization (DO) and Dose Escalation (DE) Update in Advanced Hepatocellular Carcinoma (HCC) • 1678RO - Phase 3 LEAP-012 Study of Lenvatinib + Pembrolizumab vs Dual Placebo With Transarterial Chemoembolization (TACE) for Unresectable Non-metastatic Hepatocellular Carcinoma: Long-term OS Results • 1680RO - Phase I study of C-CAR031, a GPC3-targeted TGFβRIIDN armored autologous CAR-T, in advanced hepatocellular carcinoma (aHCC): Updated Results [Slide 3 — NET/NEC] • 2395RO - Concomitant Somatostatin Analog Use In Second-Line Therapy Of Gastroenteropancreatic Neuroendocrine Tumors: Survival Results From The Retrospective RetroSAUNA Study • 2396RO - Cohort level safety and efficacy results for [212Pb]VMT-a-NET in advanced somatostatin receptor subtype 2 (SSTR2+)-expressing neuroendocrine tumors (NETs): Cohorts 1–3 • 2394RO - Latest efficacy and safety analysis of surufatinib combined with EP regimen and serplulimab as first-line treatment for extrapulmonary neuroendocrine carcinoma • 2397RO - Subgroup analysis of the ongoing Phase Ib DAREON®-7 study: Outcomes with first-line (1L) obrixtamig plus standard of care (SoC) in neuroendocrine carcinomas (NECs) by DLL3 expression status • LBA57 - Opamtistomig (LBL-024) monotherapy in advanced extra-pulmonary neuroendocrine carcinoma (EP-NEC) after ≥2 prior lines of therapies: results from a pivotal, registrational phase IIb study of a novel PD-L1×4-1BB bispecific antibody • 2392O - Opamtistomig (LBL-024), a novel PD-L1×4-1BB bispecific antibody, combined with chemotherapy as first-line treatment for advanced extrapulmonary neuroendocrine carcinoma: results from a phase Ib/II trial • 2393O - First results from a phase 2 trial of second-line pumitamig (PD-L1 × VEGF-A bsAb) plus chemotherapy in unresectable neuroendocrine neoplasms [Slide 4 — Pancreatic] • LBA82 - Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Additional subgroup analyses from the Ph3 RASolute 302 study. • LBA83 - Seven-Valent mKRAS-specific Lymph Node Targeted Amphiphile Immunotherapy Versus Observation in Resected Pancreatic Ductal Adenocarcinoma (PDAC): the AMPLIFY-7P randomized Phase 2 study • 3136RO - Randomised Phase II study of mFOLFIRINOX±SBRT in patients with high risk, borderline resectable or locally advanced pancreatic cancer: Results of the AGITG MASTERPLAN trial • LBA84 - A randomized, multicenter, open-label, double-arm, phase III study of doublet vs. monotherapy in advanced pancreatic cancer patients who have failed first-line therapy. (Panc-SELECT - Gemcitabine arms). • LBA85 - HRS-4642 Plus Chemotherapy ± Adebrelimab as Perioperative Therapy in KRAS G12D-Mutant Pancreatic Cancer: Preliminary Results of a Phase 2 Study • 3137RO - Safety and Efficacy of INCB161734, a Novel Oral KRAS G12D Inhibitor, in Combination with Chemotherapy in Patients (pts) with Advanced/Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

[Slide 1] MY TOP 10 BREAST CANCER ABSTRACTS #ESMO26 (@dr_yakupergun): 01 · LBA23 TALENT — Final results: Neoadjuvant T-DXd with or without anastrozole, or in sequence with chemotherapy, in HER2-low, HR+ early breast cancer. Sara A. Hurvitz. 02 · LBA25 NATALEE — Adjuvant ribociclib + NSAI in HR+/HER2− early breast cancer: 6-year overall survival and efficacy outcomes. Dennis J. Slamon. 03 · LBA50 PANKU-Breast01 — Phase III izalontamab brengitecan in previously treated unresectable locally advanced or metastatic HR+/HER2− breast cancer. Bo Lan. 04 · LBA51 KEYNOTE-B49 — Phase III pembrolizumab vs placebo plus chemotherapy in HR+/HER2− advanced breast cancer. Hope S. Rugo. 05 · LBA14 FINER — Overall survival with fulvestrant + ipatasertib in ER+/HER2− metastatic breast cancer. Andrew D. Redfern. 06 · LBA16 VIKTORIA-1 — Updated phase III results: Gedatolisib + fulvestrant ± palbociclib vs standard of care in HR+/HER2− advanced breast cancer. Barbara Pistilli. 07 · 1RO postMONARCH — Overall survival: Abemaciclib + fulvestrant vs placebo + fulvestrant after progression on prior CDK4/6 inhibitor + endocrine therapy. Kevin Kalinsky. 08 · 2RO evERA Breast Cancer — Retrospective exploratory biomarker analyses from phase III evERA: Giredestrant + everolimus in ER+/HER2− advanced breast cancer after CDK4/6 inhibitor. Sara M. Tolaney. 09 · 3RO OptiTROP-Breast01 — Final OS analysis: Sacituzumab tirumotecan vs chemotherapy in previously treated locally recurrent or metastatic TNBC. Man Li. 10 · 4RO SWITCH — Phase II target switching with conserved-payload novel ADCs after prior ADC therapy. Lei Fan.

[Slide 1] Proffered Paper session — 2613O - Primary results of SARON: a randomised-controlled trial of consolidation radiotherapy for synchronous oligometastatic non-small cell lung cancer. Speakers: Fiona McDonald (London, United Kingdom). Duration: 10 Minutes. Proffered Paper session — 2614O - Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC with PD-L1 ≥50%: PERSEE phase 3 trial (GFPC 01-2020). Speakers: Chantal Decroisette (Lyon, France, CEDEX). Duration: 10 Minutes.

[Slide 1] LBA3 - Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial. Speakers: Jacob Sands (Boston, United States of America). Duration: 12 Minutes. [Slide 2] LBA5 - Krascendo 1: efficacy and safety of divarasib (diva) vs sotorasib (soto) or adagrasib (ada) in previously treated locally advanced or metastatic KRAS G12C-mutated NSCLC. Speakers: Ferdinandos Skoulidis (Houston, United States of America, TX). Duration: 12 Minutes. [Slide 3] LBA6 - Osimertinib (osi) + savolitinib (savo) vs platinum–pemetrexed (plat–pem) in EGFRm MET-overexpressed (OE) and/or -amplified (AMP) advanced NSCLC post-osi: SAFFRON Phase (Ph) 3 primary results. Speakers: Shun Lu (Shanghai, China). Duration: 12 Minutes.

[Slide 1] 5. Conclusions — In conclusion, our real-world experience provides supportive evidence that tarlatamab is an active and tolerable therapeutic agent for heavily pretreated patients with advanced SCLC. The findings are consistent with the utility of tarlatamab in SCLC. However, our study suggests that caution is warranted when considering the off-label extrapolation of SCLC therapies to EPSCC based solely on shared histology. The absence of responses in this small, biologically heterogeneous series without DLL3 testing raises a hypothesis that requires prospective biomarker-correlated evaluation and does not permit definitive conclusions regarding efficacy in EPSCC.

[Slide 1] Presidential Symposium I — Date: Sat, 24.10.2026 · Room: Alicante Auditorium - Hall 6 · Time: 16:30 - 18:15. LBA1 - INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL). Speakers: Georgina V. Long (Sydney, Australia, NSW). Duration: 12 Minutes. Invited Discussant LBA1. Duration: 12 Minutes. LBA2 - Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: results from the Phase 3 VOLGA trial. Speakers: Thomas B. Powles (London, United Kingdom). Duration: 12 Minutes. [Slide 2] LBA3 - Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial. Speakers: Jacob Sands (Boston, United States of America). Duration: 12 Minutes. Invited Discussant LBA3. Duration: 12 Minutes. LBA4 - Darolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: interim analysis of an international, placebo-controlled, randomised phase 3 trial (DASL-HiCaP; ANZUP1801). Speakers: Tamim Niazi (Montreal, Canada, QC). Duration: 12 Minutes.